Efzimfotase Alfa Misses Significance in HPP Phase 3 HICKORY Trial
Efzimfotase alfa showed numerical gains in the HICKORY phase 3 trial for hypophosphatasia, but the 6MWT endpoint did not reach statistical significance.
This section contains the website’s posts.